Dhananjay Kapse
Pune, MH, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Persistence of Serum Bactericidal Antibody in the First 2-Years After Immunization with Pentavalent Meningococcal ACWYX Vaccine in Malian Infants and Toddlers.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 31, 2026
Comparison of VPM1002 with BCG in the prevention of tuberculosis in newborn infants: a multicentre, double-blind, randomised, phase 3, non-inferiority trial.
Journal: The Lancet. Infectious diseases
Published: February 19, 2026
Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.
Journal: Lancet (London, England)
Published: January 02, 2025
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.
Journal: Lancet (London, England)
Published: October 04, 2024
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study.
Journal: The Lancet. Infectious diseases
Published: June 05, 2024
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
Journal: Human vaccines & immunotherapeutics
Published: March 21, 2024
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
Journal: JAMA pediatrics
Published: July 31, 2023
Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.
Journal: The New England journal of medicine
Published: May 24, 2023
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Journal: Scientific reports
Published: February 10, 2023
Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure.
Journal: The Lancet regional health. Southeast Asia
Published: January 30, 2023
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study.
Journal: The Lancet regional health. Southeast Asia
Published: August 10, 2022
A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.
Journal: EClinicalMedicine
Published: August 19, 2021
Last Updated: 09/26/2026